论文部分内容阅读
在理论上,急性心梗早期静脉给予卡托普利和 rt-PA 可能减少左室容量,防止心室扩张和改善病人生存。为了验证早期静脉给予卡托普利和 rt-PA 的安全性和有效性,在心梗发生后3±0.3小时((?)±SE),用 rt-PA治疗的38例病人被随机分为卡托普利组和安慰剂组。卡托普利先静脉注射,随后口服。在第1和7天,进行心导管检查,测定血流动力学变量、左室功能以及肾素、血管紧张素和醛固酮的浓度。继续口服下列药物:卡托普利或安慰剂;其它抗心绞痛药物,包括非血管紧张素转换酶抑制剂类血管扩张剂。在出院前和3个月时复查左室功能。两组的基本临床特征没有显著差异。卡托普利组1例病人在静脉用药时出现低血
In theory, early intravenous administration of captopril and rt-PA to acute myocardial infarction may reduce left ventricular volume, prevent ventricular dilatation and improve patient survival. To verify the safety and efficacy of early intravenous captopril and rt-PA, 38 patients who were treated with rt-PA at 3 ± 0.3 hours post-MI (± SE) were randomized into a card Topira group and placebo group. Captopril first intravenous injection, followed by oral. Cardiac catheterization was performed on days 1 and 7 to measure hemodynamic variables, left ventricular function, and concentrations of renin, angiotensin, and aldosterone. Continue oral administration of the following drugs: captopril or placebo; other anti-anginal drugs, including non-angiotensin-converting enzyme inhibitor vasodilators. Left ventricular function was reviewed before discharge and at 3 months. There was no significant difference in the basic clinical characteristics between the two groups. One patient in captopril group developed hyponatremia during intravenous administration